04.04.2013 - Researchers from ETH Zurich have shown that the individual fingerprint of exhaled breath can be used for diagnostic purposes.
The team headed by Renato Zenobi reports in the journal PLoS that real-time analysis of the metabolic pattern found in exhaled breath can help to diagnose and monitor diseases. Using mass spectrometry (SESI-MS), the ETH researchers found that the chemical "fingerprint" of exhaled breath of 11 volunteers showed an individual core pattern and remained stable over time. According to the researchers, linking up that metabolic ID with genetic susceptibility to diseases can help diagnosing manifestation of diseases more individually. Shortly before, US researchers had published results of a MS-based study for diagnosis of heart failure.
"We did find some small variations during the day, but overall the individual pattern stays sufficiently constant to be useful for medical purposes," says Pablo Martinez-Lozano Sinues, senior scientist in Zenobi's research group. To carry out these measurements, Zenobi and his colleagues modified commercial mass spectrometers by adding a breath sampling inlet line that delivers exhaled breath from a mouth piece directly into the ion source of the instrument. Mass spectra showing peaks of roughly 100 compounds in breath can be easily and rapidly obtained.
The researchers are working to recognise characteristic patterns of lung diseases with the same technology. Although the potential usefulness of analysing breath for medical diagnosis has been known, it is rarely done in academic medicine. "This might be due to the fact that existing methods for breath analysis are either rather slow, or are limited to a small number of compounds that they can detect," says Sinues. Compared to analysis of blood or urine, a significant advantage of the ETH researchers’ approach is that the breath fingerprint is available within seconds. Another benefit is that exhaling into the ion source of a mass spectrometer is completely non-invasive. They researchers see huge potential to use the method as a tool for early detection of certain diseases in risk populations and in therapy monitoring.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
Merck’s advanced water purification system with new high-throughput line delivers up to 9,000 liters of pure water daily with real-time monitoring and ensures constant water quality with low and predictable running costs. more